Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH). However, there is little information about the transition strategy between these two ETRAs. We aimed to evaluate the safety and effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Su-Gang, Wang, Lan, Pudasaini, Bigyan, Yuan, Ping, Jiang, Rong, Zhao, Qin-Hua, He, Jing, Zhang, Rui, Wu, Wen-hui, Liu, Jin-Ming, Zhou, Cai-cun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924990/
https://www.ncbi.nlm.nih.gov/pubmed/29849836
http://dx.doi.org/10.1155/2018/9836820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924990/
https://www.ncbi.nlm.nih.gov/pubmed/29849836
http://dx.doi.org/10.1155/2018/9836820

Ejemplares similares